Selected phase 3 trials in relapsed disease
| Reference . | Name of trial . | No. prior lines . | Arm . | N . | PFS* . | HR . | ORR . | ≥VGPR . | ≥CR . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dimopoulos et al27 | ENDEAVOR | 1-3 | Kd | 464 | 18.7 | 0.53 | 77% | 54% | 13% | |
| Vd | 465 | 9.4 | 63% | 29% | 6% | |||||
| Moreau et al29 | TOURMALINE-MM1 | 1-3 | IRd | 360 | 20.6 | 0.74 | 78% | 48% | 12% | |
| Rd | 362 | 14.7 | 72% | 39% | 7% | |||||
| Lonial et al42 | ELOQUENT-2 | 1-3 | Elo-Rd | 321 | 19.4 | 0.7 | 79% | 33% | 4% | |
| Rd | 325 | 14.9 | 66% | 28% | 7% | |||||
| Stewart et al28 | ASPIRE | 1-3 | KRd | 396 | 26.3 | 0.69 | 87% | 70% | 32% | |
| Rd | 396 | 17.6 | 67% | 40% | 9% | |||||
| San Miguel et al36 | PANORAMA 1 | 1-3 | Pano-Vd | 387 | 11.99 | 0.63 | 61% | 11% | ||
| Vd | 381 | 8.08 | 55% | 6% | ||||||
| San Miguel et al30 | NIMBUS (MM-003) | ≥2† | Pd | 302 | 4.0 | 0.48 | 31% | 6% | 1% | |
| D | 153 | 1.9 | 10% | 1% | 0% | |||||
| Palumbo et al48 | CASTOR | ≥1 | Vd-dara | 251 | NE | 0.39 | 82.9% | 59.2% | 19.2% | |
| Vd | 247 | 7.2 | 63.2% | 29.1% | 9% | |||||
| Dimopoulos et al49 | POLLUX | ≥1 | Rd-dara | 286 | NE | 0.37 | 93% | 76% | 43% | |
| Rd | 283 | 18.4 | 76% | 44% | 19% | |||||
| Reference . | Name of trial . | No. prior lines . | Arm . | N . | PFS* . | HR . | ORR . | ≥VGPR . | ≥CR . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dimopoulos et al27 | ENDEAVOR | 1-3 | Kd | 464 | 18.7 | 0.53 | 77% | 54% | 13% | |
| Vd | 465 | 9.4 | 63% | 29% | 6% | |||||
| Moreau et al29 | TOURMALINE-MM1 | 1-3 | IRd | 360 | 20.6 | 0.74 | 78% | 48% | 12% | |
| Rd | 362 | 14.7 | 72% | 39% | 7% | |||||
| Lonial et al42 | ELOQUENT-2 | 1-3 | Elo-Rd | 321 | 19.4 | 0.7 | 79% | 33% | 4% | |
| Rd | 325 | 14.9 | 66% | 28% | 7% | |||||
| Stewart et al28 | ASPIRE | 1-3 | KRd | 396 | 26.3 | 0.69 | 87% | 70% | 32% | |
| Rd | 396 | 17.6 | 67% | 40% | 9% | |||||
| San Miguel et al36 | PANORAMA 1 | 1-3 | Pano-Vd | 387 | 11.99 | 0.63 | 61% | 11% | ||
| Vd | 381 | 8.08 | 55% | 6% | ||||||
| San Miguel et al30 | NIMBUS (MM-003) | ≥2† | Pd | 302 | 4.0 | 0.48 | 31% | 6% | 1% | |
| D | 153 | 1.9 | 10% | 1% | 0% | |||||
| Palumbo et al48 | CASTOR | ≥1 | Vd-dara | 251 | NE | 0.39 | 82.9% | 59.2% | 19.2% | |
| Vd | 247 | 7.2 | 63.2% | 29.1% | 9% | |||||
| Dimopoulos et al49 | POLLUX | ≥1 | Rd-dara | 286 | NE | 0.37 | 93% | 76% | 43% | |
| Rd | 283 | 18.4 | 76% | 44% | 19% | |||||
D, high-dose dexamethasone; d, low-dose dexamethasone; dara, daratumumab; I, ixazomib; K, carfilzomib; NE, not estimable; P, pomalidomide; Pano, panobinostat; R, lenalidomide; V, bortezomib.
PFS is in months.
Refractory to prior therapy; ≥2 cycles of bortezomib and lenalidomide, alone or in combination; adequate alkylator treatment (or as part of stem cell transplant).